-
Streetinsider.com's Hot Lunchtime Reads 9/28: (BID) (GALE) (AAPL) (QSR)
-
Roth Affirms Galena Biopharma (GALE) at 'Buy' Fllowing GALE-301 Phase 2a Update; 1000 mcg Seen as Optimal
-
Roth Capital Remains Positive on Galena Biopharma (GALE) Following Zuplenz Launch
-
Galena Biopharma's (GALE) GALE-401 Phase 2 Shows Potential Advantage of IR formulation; Roth Affirms at 'Buy'
-
Streetinsider.com's Hot Lunchtime Reads 5/22: (DGX) (AAPL) (AWR) (DE)
-
Roth Capital 'Encouraged' by Latest GALE-401 Phase 2 Data; Affirms 'Buy' Rating on Galena Biopharma (GALE)
-
Over-Enrollment in Galena's (GALE) Phase III PRESENT Should Strengthen Validity of Results - Roth Capital
-
Galena Biopharma Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million
-
Roth Comments on Galena's (GALE) Expanded NeuVax, Trastuzumab Enrollments; Affirms 'Buy' Rating
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
Galena Biopharma (GALE) Prices 24.4M Common, Warrants Offering at $1.56/Unit
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Roth Affirms Galena Biopharma (GALE) at 'Buy' Following Q4 Report; Still Sees FY15/FY16 as Busy Time Frame
-
Roth Adjusts Ests on Galena (GALE) Following FY15 Net Revs Outlook; 2015 Will be 'Busy Year' for Company
-
Galena's (GALE) GALE-401 More Promising Following Presentation Phase 2 Data at ASH - Roth
-
Roth Capital Positive on Galena (GALE) Following Quick Enrollment of GALE-401 Phase 2
-
Roth Comments on Galena (GALE) Following Initiation of Herceptin Combo Trial
-
Roth Cap Remains Positive on Galena Biopharma (GALE) Following Q3 Results, Update
-
Roth Lowers Ests on Galena Biopharma (GALE) Following Special Committee Report
-
Roth Capital Comments on Buy-Rated Galena (GALE) Following CEO Transition
-
Roth Capital Raises PT on Galena (GALE) to $8 Following Zuplenz Licensing News
-
Roth 'Impressed' at Early Completion of Enrollment in Galena's (GALE) GALE-301 Phase 2a; Keeps at 'Buy'
-
Roth Still Positive on Galena Biopharma (GALE) Following GALE-301 FBP Presentation; Issues Commentary
-
Roth Keeps Galena (GALE) at 'Buy' Following Q1 Report; Still Bullish on Abstral Following Revenue Results
-
DoD Supporting Galena's (GALE) NeuVax Provides Important Third-Party Scientific Validation - Roth
-
Roth Cuts PT on Galena Biopharma (GALE) on SEC Risk
-
Roth Capital Raises PT on Galena Biopharma (GALE) Following Deal with Dr. Reddy's (RDY)
-
Notable 52-Week Highs and Lows of the Day 01/13: (RNN) (NVAX) (SWKS) High; (LULU) (SODA) Low
-
Notable Mergers and Acquisitions of the Day 01/13: (BEAM) (GG) (GALE) (FWLT) (VC)/(JCI)
-
Roth Capital Raises PT on Galena Biopharma (GALE) Following Mills Pharmaceuticals Purchase
-
Galena Biopharma (GALE) Acquires GALE-401 Rights Owner, Mills Pharmaceuticals
-
Galena Biopharma Acquires Mills Pharmaceuticals, LLC
-
Galena Biopharma (GALE) Prices 17.5M Offering at $2/Unit
-
Galena (GALE) Prices 8.5M Offering at $1.50/Share
-
After-Hours Movers 04/04: (APP) (BBBY) (BAS) Higher; (GALE) (RT) (CKEC) (HEAT) Lower
-
Galena Biopharma (GALE) Announces Common Offering
-
Unusual 11 Mid-Day Movers 03/29: (DEER) (OPHC) (IDRA) Higher; (CHTP) (SABA) (AH) Lower